July 06, 2022
Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias.
June 27, 2022
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
June 15, 2022
The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.
May 20, 2022
The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
May 06, 2022
Janet E McDonagh, MD, FRCP, discusses the study “The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis.”
April 26, 2022
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.
April 21, 2022
Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.
March 30, 2022
Chronic stressors may play an important role in the development of chronic pain, leading to excess cortisol production and disruption to the body's sympathetic and parasympathetic systems.
March 24, 2022
Limited physical function, fatigue, mental health issues (resulting from chronic disease), and medication issues can further affect the ability of children with rheumatic disease from performing well in school.
March 15, 2022
Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.